New Zealand - Tiếng Anh - Ministry for Primary Industries

bayer new zealand limited - prothioconazole - emulsifiable concentrate - prothioconazole 250 g/litre - fungicide - fungicide

New Zealand - Tiếng Anh - Ministry for Primary Industries

bayer new zealand limited - phenmedipham; desmedipham - phenmedipham 160 g/litre; desmedipham 160 g/litre - herbicide

New Zealand - Tiếng Anh - Ministry for Primary Industries

bayer new zealand limited - triadimenol; fluopyram - suspension concentrate - triadimenol 250 g/litre; fluopyram 250 g/litre - fungicide - fungicide

New Zealand - Tiếng Anh - Ministry for Primary Industries

bayer new zealand limited - tebuconazole; fluopyram; prothioconazole - flowable concentrate - tebuconazole 60 g/litre; fluopyram 20 g/litre; prothioconazole 100 g/litre - fungicide - seedgrowth

New Zealand - Tiếng Anh - Ministry for Primary Industries

bayer new zealand limited - pyroxasulfone - pyroxasulfone 850 g/kg - herbicide

New Zealand - Tiếng Anh - Ministry for Primary Industries

bayer new zealand limited - tebuconazole; prothioconazole - emulsifiable concentrate - tebuconazole 80 g/litre; prothioconazole 160 g/litre - fungicide - fungicide

Israel - Tiếng Anh - Ministry of Health

amgen europe b.v. - carfilzomib - powder for solution for injection - carfilzomib 2 mg/ml - carfilzomib - kyprolis is indicated: - for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy in combination with: • lenalidomide and dexamethasone; or • dexamethasone; or • daratumumab (i.v or s.c) and dexamethasone.- as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. approval is based on response rate. clinical benefit, such as improvement in survival or symptoms, has not been verified.

Israel - Tiếng Anh - Ministry of Health

amgen europe b.v. - carfilzomib - powder for solution for injection - carfilzomib 2 mg/ml - carfilzomib - kyprolis is indicated: o for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy in combination with: • lenalidomide and dexamethasone; or • dexamethasone; or • daratumumab (i.v or s.c) and dexamethasone.o in combination with isatuximab and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.o as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. approval is based on response rate. clinical benefit, such as improvement in survival or symptoms, has not been verified.

Úc - Tiếng Anh - myHealthbox

ecolab -

Israel - Tiếng Anh - Ministry of Health

abic marketing ltd, israel - armodafinil - tablets - armodafinil 150 mg - modafinil - nuvigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (osa), narcolepsy, or shift work disorder (swd).